Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
9.50
+0.49 (5.44%)
Aug 28, 2026, 12:44 PM EDT - Market open
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$5,160,000
Market Cap
18.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Citius Pharmaceuticals | 23 |
| BioCardia | 21 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| Lipocine | 14 |
| BioVie | 13 |
| Psyence Biomedical | 12 |
AKTX News
- 1 day ago - Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - GlobeNewsWire
- 10 days ago - Akari Therapeutics reports new AKTX-101 preclinical data - TheFly
- 10 days ago - Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy - GlobeNewsWire
- 14 days ago - Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform - GlobeNewsWire
- 15 days ago - Akari Therapeutics, Quarterly report: Q2 2026 - Filings
- 15 days ago - Akari Therapeutics, Earnings release: Q2 2026 - Filings
- 24 days ago - Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - GlobeNewsWire
- 5 weeks ago - Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - GlobeNewsWire